好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Quality of Life in Sexual and Gender Minorities: A Pioneer Cross-sectional Study
Health Care Disparities
P3 - Poster Session 3 (5:30 PM-6:30 PM)
4-010
Determine quality of life characteristics among sexual and gender minority (SGM) people living with epilepsy.
SGM people account for 8% of the total American adult population.1 Nonetheless, epilepsy data regarding SGM people are scarce.2 Data on physical and mental quality of life (QOL) aspects among SGM people with epilepsy (PWE) are unknown. 
As part of a quality improvement initiative, data was collected using electronic patient-report questionnaires from January 2019 to September 2023 in a tertiary epilepsy clinic. We analyzed PWE’s physical and mental QOL aspects using the PROMIS-10 questionnaire. We categorized patients by sexual orientation and gender identity. Descriptive statistics were performed comparing SGM patients to cisgender heterosexual patients.
Data regarding sexual orientation was available for 2230 patients, of whom 164 (7.35%) identified as sexual minority people. Data regarding gender identity was available for 2623 patients, of whom 24 (0.91%) identified as transgender. Only 25 SGM (including 3 transgender) patients and 433 cisgender heterosexual patients completed PROMIS 10 questionnaires. Among cisgender heterosexual patients, median values from mental and physical sections of PROMIS 10 were 45.8 (IQR 14.5) and 50.8 (IQR 15.4) respectively. Median values among all SGM patients were 41.1 (IQR 14.5) and 47.7 (IQR 11.8) respectively. Median values among sexual minority patients were 43.55 (IQR 25.2) and 46.3 (IQR 14.85), respectively.  Median values among transgender people were 53.30 (IQR 37.8) and 42.30 (IQR 15.9), respectively

Our data suggest different QOL metrics when stratified by gender identity and sexual orientation. No test of significance was performed due to the high rates of missing data, which calls for further research to improve data completion that may reveal healthcare disparities among SGM people.
Authors/Disclosures
Levi Coelho Maia Barros, MD
PRESENTER 		Mr. Coelho Maia Barros has nothing to disclose.
Aya ElHassan (MGH) Aya ElHassan has nothing to disclose.
Julianne Brooks Julianne Brooks has nothing to disclose.
Caroline Banfi (MGH) No disclosure on file
Maria Donahue (Massachusetts General Hospital) Maria Donahue has nothing to disclose.
Chelsea Wong (Hebrew SeniorLife) No disclosure on file
Z P. L'Erario, MD, LMSW Dr. L'Erario has received publishing royalties from a publication relating to health care.
Alison Kukla (Partners Against Mortality in Epilepsy) Alison Kukla has received personal compensation for serving as an employee of Epilepsy Foundation of America. Alison Kukla has received personal compensation for serving as an employee of Dartmouth Health. Alison Kukla has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB Biosciences Inc. Alison Kukla has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurelis. Alison Kukla has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant with International Bureau for Epilepsy. Alison Kukla has received personal compensation in the range of $50,000-$99,999 for serving as a PAME, Senior Advisor with American Epilepsy Society.
Brandy Fureman, PhD Dr. Fureman has received personal compensation for serving as an employee of Epilepsy Foundation. Dr. Fureman has or had stock in EnlitenAI. The institution of Dr. Fureman has received research support from Jazz Pharmaceuticals, Inc. The institution of Dr. Fureman has received research support from NINDS/NIH. The institution of Dr. Fureman has received research support from CDC. Dr. Fureman has a non-compensated relationship as a Owner with Neuroscience Navigators, LLC that is relevant to AAN interests or activities.
Jeffrey R. Buchhalter, MD, FAAN (Buchhalter Consulting PLLC) Dr. Buchhalter has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Epilepsy Foundation. Dr. Buchhalter has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Epilepsy Study Consortium. Dr. Buchhalter has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Dr. Buchhalter has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biocodex. Dr. Buchhalter has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Dr. Buchhalter has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biocodex. Dr. Buchhalter has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Neurona.
Sahar Zafar, MD Dr. Zafar has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer. Dr. Zafar has received research support from NIH. Dr. Zafar has received personal compensation in the range of $5,000-$9,999 for serving as a Speaker for a lecture with Marinus.
Lidia Maria V. Moura, MD, PhD, MPH, FAAN (Massachusetts General Hospital) Dr. Moura has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for UCB. Dr. Moura has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pfizer. The institution of Dr. Moura has received research support from Centers for Diseases Control and Prevention (CDC SIP20-007) . The institution of Dr. Moura has received research support from Epilepsy Foundation of America . The institution of Dr. Moura has received research support from NIH - NIA and NINDS. Dr. Moura has received personal compensation in the range of $50,000-$99,999 for serving as a Expert Advisor with Epilepsy Foundation .